ELTX is trading 6.1% up at $4.15 in pre-market as the micro-cap biotech rebounds from a recent pullback amid ongoing optimism surrounding its pancreatic cancer treatment data.
- Investors continue to react to positive results for lead candidate ELI-002 7P and the company’s Phase 2/Phase 3 development narrative.
- The stock is attracting attention as a high-volatility micro-cap play, though no new company-specific catalysts have been released this morning.